Nicolas Chausson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicolas Chausson has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Gaultier Marnat
Department of Neuroradiology, Bordeaux University Hospital, Bordeaux, France
6 shared publications - Didier Smadja
Centre hospitalier Sud-Francilien, Corbeil-Essonnes, France
5 shared publications - Frédéric Clarençon
Department of Neuroradiology, Pitie-Salpetriere Hospital, Paris, France
5 shared publications - Guillaume Turc
Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (N.C., J.B., W.B.H., D.S., G.T.).
5 shared publications - Stéphane Olindo
Centre Hospitalier Universitaire (CHU) de Bordeaux, Neurologie Vasculaire, France (M. Boullet, S.O., I.S.).
5 shared publications - Wagih Ben Hassen
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France
5 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3224-3232
Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study
BACKGROUND: Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain. METHODS: This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016–2018) or tenecteplase (0.25 mg/kg, 2018–2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020–2023 versus 2016–2019). RESULTS: Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1–7) in the tenecteplase group versus 4 (1–7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70–94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting–odds ratio, 1.59 [95% CI, 1.15–2.20]; P =0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting–odds ratio, 0.49 [95% CI, 0.35–0.69]; P <0.0001). CONCLUSIONS: Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05635786.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3224-3232
Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study
BACKGROUND: Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain. METHODS: This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016–2018) or tenecteplase (0.25 mg/kg, 2018–2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020–2023 versus 2016–2019). RESULTS: Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1–7) in the tenecteplase group versus 4 (1–7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70–94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting–odds ratio, 1.59 [95% CI, 1.15–2.20]; P =0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting–odds ratio, 0.49 [95% CI, 0.35–0.69]; P <0.0001). CONCLUSIONS: Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05635786.
- Open Access
- 23 September 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 105
Effect Modification of Rescue Stenting in ICAS-Related Middle Cerebral Artery Occlusion: The Role of Thrombectomy Failure, Stenosis Severity, and ASPECTS
Rescue stenting (RS) is increasingly used for intracranial artery stenosis-related large vessel occlusion (ICAS-LVO), but optimal patient selection remains uncertain. We investigated the baseline and procedural factors associated with receiving RS and whether they modified the association between RS and clinical outcome. This retrospective multicenter study included patients with middle cerebral artery (MCA) ICAS-LVO treated with mechanical thrombectomy (MT) alone or MT followed by RS. Baseline and procedural characteristics associated with receiving RS were identified using multivariable logistic regression and incorporated into inverse probability of treatment weighting models to assess treatment-effect heterogeneity for the 90-day modified Rankin Scale score. Among 264 patients, 193 received RS and 71 MT alone. MT failure, severe stenosis (> 75%), and higher baseline Alberta Stroke Program Early CT Score (ASPECTS) were independently associated with receiving RS. Both MT failure (interaction OR 0.28, 95% CI 0.10–0.83; p for interaction = 0.02) and severe stenosis (interaction OR 0.13, 95% CI 0.03–0.53; p for interaction = 0.004) significantly modified the association between RS and clinical outcome, whereas baseline ASPECTS did not. Within the MT failure subgroup, a significant interaction between severe stenosis and ASPECTS was observed (interaction OR 0.08, 95% CI 0.02–0.38; p for interaction = 0.002), suggesting a more favorable association between RS and outcome at higher ASPECTS values in patients with severe stenosis. In MCA ICAS-LVO, RS may be associated with more favorable outcomes in patients with MT failure, particularly in the presence of severe residual stenosis and preserved ASPECTS. These findings support a more selective approach to RS and warrant prospective validation.
- 23 September 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 105
Open AccessEffect Modification of Rescue Stenting in ICAS-Related Middle Cerebral Artery Occlusion: The Role of Thrombectomy Failure, Stenosis Severity, and ASPECTS
Rescue stenting (RS) is increasingly used for intracranial artery stenosis-related large vessel occlusion (ICAS-LVO), but optimal patient selection remains uncertain. We investigated the baseline and procedural factors associated with receiving RS and whether they modified the association between RS and clinical outcome. This retrospective multicenter study included patients with middle cerebral artery (MCA) ICAS-LVO treated with mechanical thrombectomy (MT) alone or MT followed by RS. Baseline and procedural characteristics associated with receiving RS were identified using multivariable logistic regression and incorporated into inverse probability of treatment weighting models to assess treatment-effect heterogeneity for the 90-day modified Rankin Scale score. Among 264 patients, 193 received RS and 71 MT alone. MT failure, severe stenosis (> 75%), and higher baseline Alberta Stroke Program Early CT Score (ASPECTS) were independently associated with receiving RS. Both MT failure (interaction OR 0.28, 95% CI 0.10–0.83; p for interaction = 0.02) and severe stenosis (interaction OR 0.13, 95% CI 0.03–0.53; p for interaction = 0.004) significantly modified the association between RS and clinical outcome, whereas baseline ASPECTS did not. Within the MT failure subgroup, a significant interaction between severe stenosis and ASPECTS was observed (interaction OR 0.08, 95% CI 0.02–0.38; p for interaction = 0.002), suggesting a more favorable association between RS and outcome at higher ASPECTS values in patients with severe stenosis. In MCA ICAS-LVO, RS may be associated with more favorable outcomes in patients with MT failure, particularly in the presence of severe residual stenosis and preserved ASPECTS. These findings support a more selective approach to RS and warrant prospective validation.
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Accidents vasculaires cérébraux en Martinique : Aspects épidémiologiques, étiologiques et thérapeutiques
L’objet de cette thèse est de présenter les spécificités épidémiologiques, étiologiques et thérapeutiques de la pathologie neurovasculaire dans la population noire spécifique que constitue la population martiniquaise. En 1998, l’étude ERMANCIA I a permis de mettre en évidence une surincidence des accidents vasculaires cérébraux (AVC) en Martinique d’environ 40% par rapport à la métropole avec une haute prévalence de l’hypertension artérielle et du diabète. Ces résultats ont participé à la création en 2003 de la 1ère unité neurovasculaire aux Antilles. Le suivi à 5 ans des patients ERMANCIA I a révélé que la moitié était décédée et que 50% des survivants présentaient une démence vasculaire (soit le double des cohortes métropolitaines), probablement favorisé par une microangiopathie cérébrale sous-jacente souvent sévère amplifiant l’impact cognitif de l’AVC. Ce suivi a également permis d’identifier les faiblesses de la prévention secondaire en Martinique avec près de 80% des hypertendus qui restent mal équilibrés justifiant la création en 2006 d’un réseau de prévention. L’efficacité de ce réseau a été évaluée montrant un taux élevé de bon contrôle tensionnel (74% vs 39%, p=0,01) et une morbi-mortalité vasculaire moindre à 2,5 ans (8,3% vs 24%, p<0,001) que chez les patients contrôles. En 2012, ERMANCIA II a permis de révéler une diminution majeure (en moyenne 30%) de l’incidence des AVC dans la population martiniquaise et de la mortalité à 1 mois pour les patients ≤55 ans (20% vs 8%, p=0,03) probablement en raison d’une meilleure implémentation des mesures de prévention primaire et de la prise en charge en UNV respectivement. Nos données ont également permis de décrire certaines spécificités étiologiques des AVC chez les Martiniquais : grande fréquence de l’athérome intracrânien (pour lequel nous apportons des arguments en faveur d’une nouvelle classification), infarctus choroïdiens antérieurs dont nous décrivons le profil évolutif particulier, infarctus lacunaires multiples sévères. Deux étiologies plus « classiques » comme la drépanocytose et les IC sur morsure de serpent sont devenues anecdotiques. En revanche, une dysplasie carotidienne focale, étiologie déjà décrite mais supposée rare , pourrait être responsable d’un tiers des infarctus carotidiens d’origine indéterminée chez les Afro-Caribéens ≤55 ans exposant à un risque élevé de récidive sous traitement antiagrégant (28% à 14 mois), contre aucun pour les patients traités par endartériectomie. Sur le plan thérapeutique, nos résultats sont en faveur d’un surrisque hémorragique de la thrombolyse standard chez les patients martiniquais les plus âgés, probablement en rapport avec un cumul de lésions microangiopathiques plus important. En l’absence de neuroradiologie interventionnelle en Martinique, nos travaux montrent que certains patients avec occlusion artérielle proximale résistante à la thrombolyse IV standard peuvent bénéficier d’un complément de thrombolytique (0,1mg/Kg de tenecteplase). Une étude randomisée est prévue afin de mieux mesurer le potentiel thérapeutique de cette stratégie. Pour conclure, l’intérêt de ces données est que la population martiniquaise partage très probablement beaucoup de ses « particularités » avec d’autres populations noires encore peu décrites et pour lesquelles l’occidentalisation progressive du mode de vie risque d’accentuer le fardeau représenté par les AVC.
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Accidents vasculaires cérébraux en Martinique : Aspects épidémiologiques, étiologiques et thérapeutiques
L’objet de cette thèse est de présenter les spécificités épidémiologiques, étiologiques et thérapeutiques de la pathologie neurovasculaire dans la population noire spécifique que constitue la population martiniquaise. En 1998, l’étude ERMANCIA I a permis de mettre en évidence une surincidence des accidents vasculaires cérébraux (AVC) en Martinique d’environ 40% par rapport à la métropole avec une haute prévalence de l’hypertension artérielle et du diabète. Ces résultats ont participé à la création en 2003 de la 1ère unité neurovasculaire aux Antilles. Le suivi à 5 ans des patients ERMANCIA I a révélé que la moitié était décédée et que 50% des survivants présentaient une démence vasculaire (soit le double des cohortes métropolitaines), probablement favorisé par une microangiopathie cérébrale sous-jacente souvent sévère amplifiant l’impact cognitif de l’AVC. Ce suivi a également permis d’identifier les faiblesses de la prévention secondaire en Martinique avec près de 80% des hypertendus qui restent mal équilibrés justifiant la création en 2006 d’un réseau de prévention. L’efficacité de ce réseau a été évaluée montrant un taux élevé de bon contrôle tensionnel (74% vs 39%, p=0,01) et une morbi-mortalité vasculaire moindre à 2,5 ans (8,3% vs 24%, p<0,001) que chez les patients contrôles. En 2012, ERMANCIA II a permis de révéler une diminution majeure (en moyenne 30%) de l’incidence des AVC dans la population martiniquaise et de la mortalité à 1 mois pour les patients ≤55 ans (20% vs 8%, p=0,03) probablement en raison d’une meilleure implémentation des mesures de prévention primaire et de la prise en charge en UNV respectivement. Nos données ont également permis de décrire certaines spécificités étiologiques des AVC chez les Martiniquais : grande fréquence de l’athérome intracrânien (pour lequel nous apportons des arguments en faveur d’une nouvelle classification), infarctus choroïdiens antérieurs dont nous décrivons le profil évolutif particulier, infarctus lacunaires multiples sévères. Deux étiologies plus « classiques » comme la drépanocytose et les IC sur morsure de serpent sont devenues anecdotiques. En revanche, une dysplasie carotidienne focale, étiologie déjà décrite mais supposée rare , pourrait être responsable d’un tiers des infarctus carotidiens d’origine indéterminée chez les Afro-Caribéens ≤55 ans exposant à un risque élevé de récidive sous traitement antiagrégant (28% à 14 mois), contre aucun pour les patients traités par endartériectomie. Sur le plan thérapeutique, nos résultats sont en faveur d’un surrisque hémorragique de la thrombolyse standard chez les patients martiniquais les plus âgés, probablement en rapport avec un cumul de lésions microangiopathiques plus important. En l’absence de neuroradiologie interventionnelle en Martinique, nos travaux montrent que certains patients avec occlusion artérielle proximale résistante à la thrombolyse IV standard peuvent bénéficier d’un complément de thrombolytique (0,1mg/Kg de tenecteplase). Une étude randomisée est prévue afin de mieux mesurer le potentiel thérapeutique de cette stratégie. Pour conclure, l’intérêt de ces données est que la population martiniquaise partage très probablement beaucoup de ses « particularités » avec d’autres populations noires encore peu décrites et pour lesquelles l’occidentalisation progressive du mode de vie risque d’accentuer le fardeau représenté par les AVC.
- 24 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (6) , e214702
IV Tenecteplase Before Thrombectomy Compared With Thrombectomy Alone in Patients With Stroke Due to a Large Vessel Occlusion
The benefit of IV thrombolysis (IVT) with alteplase before endovascular thrombectomy (EVT) compared with EVT alone has been shown to be limited and time dependent. Data on tenecteplase, its recommended alternative, are limited. We aimed to assess the efficacy and safety of IVT with tenecteplase plus mechanical thrombectomy (TNK + EVT) compared with EVT in patients with large vessel occlusion stroke and determine whether its potential benefit decreases with treatment time. We conducted a retrospective pooled analysis of 2 nationwide, real-world registries of patients with anterior circulation large vessel occlusion stroke within 4.5 hours of known symptom onset and with no contraindication to thrombolysis, treated with TNK + EVT (TETRIS) or EVT (ETIS). The efficacy outcome was the 3-month modified Rankin Scale (mRS) score, analyzed in ordinal and dichotomized (mRS score ≤2) approaches. We used propensity score-weighted logistic regression to assess associations between treatment groups and outcomes of interest. Among 1,890 patients who were analyzed (TNK + EVT: n = 798; EVT: n = 1,092; median age 73 years [interquartile range 61-82]; 49.6% women), the median expected onset-to-thrombolysis time was 146 minutes [interquartile range 119-180]. More than half of patients (n = 1,063; 56.2%) were admitted first to a primary stroke center. All baseline characteristics were balanced between treatment groups after overlap weighting. Overall, TNK + EVT was associated with better 3-month functional outcome over the full mRS (weighted common odds ratio [OR] 1.53 [95% CI 1.29-1.82]; p < 0.001) and regarding functional independence (propensity score overlap weighting [PSOW]-OR 1.50 [95% CI 1.23-1.84]; p < 0.001). This benefit did not differ statistically between patients admitted first to a primary or comprehensive stroke center (p-interaction = 0.12). There was no significant effect of the expected onset-to-thrombolysis time on the association between TNK + EVT and better functional outcome (p-interaction = 0.11). There were no significant differences in parenchymal hematoma (PSOW-OR 1.29 [95% CI 0.94-1.79]; p = 0.12) and symptomatic intracerebral hemorrhage (PSOW-OR 1.13 [95% CI 0.69-1.86]; p = 0.61) rates. Among patients treated within 4.5 hours of symptom onset, TNK + EVT was associated with better functional outcome than EVT, without safety concerns. This benefit does not seem to be time dependent. These findings support the routine use of tenecteplase before EVT in the early time window. This study provides Class II evidence that, in patients with stroke due to anterior circulation large vessel occlusion, IV tenecteplase plus thrombectomy is associated with better functional outcomes at 3 months compared with thrombectomy alone. NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry).
- 24 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (6) , e214702
IV Tenecteplase Before Thrombectomy Compared With Thrombectomy Alone in Patients With Stroke Due to a Large Vessel Occlusion
The benefit of IV thrombolysis (IVT) with alteplase before endovascular thrombectomy (EVT) compared with EVT alone has been shown to be limited and time dependent. Data on tenecteplase, its recommended alternative, are limited. We aimed to assess the efficacy and safety of IVT with tenecteplase plus mechanical thrombectomy (TNK + EVT) compared with EVT in patients with large vessel occlusion stroke and determine whether its potential benefit decreases with treatment time. We conducted a retrospective pooled analysis of 2 nationwide, real-world registries of patients with anterior circulation large vessel occlusion stroke within 4.5 hours of known symptom onset and with no contraindication to thrombolysis, treated with TNK + EVT (TETRIS) or EVT (ETIS). The efficacy outcome was the 3-month modified Rankin Scale (mRS) score, analyzed in ordinal and dichotomized (mRS score ≤2) approaches. We used propensity score-weighted logistic regression to assess associations between treatment groups and outcomes of interest. Among 1,890 patients who were analyzed (TNK + EVT: n = 798; EVT: n = 1,092; median age 73 years [interquartile range 61-82]; 49.6% women), the median expected onset-to-thrombolysis time was 146 minutes [interquartile range 119-180]. More than half of patients (n = 1,063; 56.2%) were admitted first to a primary stroke center. All baseline characteristics were balanced between treatment groups after overlap weighting. Overall, TNK + EVT was associated with better 3-month functional outcome over the full mRS (weighted common odds ratio [OR] 1.53 [95% CI 1.29-1.82]; p < 0.001) and regarding functional independence (propensity score overlap weighting [PSOW]-OR 1.50 [95% CI 1.23-1.84]; p < 0.001). This benefit did not differ statistically between patients admitted first to a primary or comprehensive stroke center (p-interaction = 0.12). There was no significant effect of the expected onset-to-thrombolysis time on the association between TNK + EVT and better functional outcome (p-interaction = 0.11). There were no significant differences in parenchymal hematoma (PSOW-OR 1.29 [95% CI 0.94-1.79]; p = 0.12) and symptomatic intracerebral hemorrhage (PSOW-OR 1.13 [95% CI 0.69-1.86]; p = 0.61) rates. Among patients treated within 4.5 hours of symptom onset, TNK + EVT was associated with better functional outcome than EVT, without safety concerns. This benefit does not seem to be time dependent. These findings support the routine use of tenecteplase before EVT in the early time window. This study provides Class II evidence that, in patients with stroke due to anterior circulation large vessel occlusion, IV tenecteplase plus thrombectomy is associated with better functional outcomes at 3 months compared with thrombectomy alone. NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry).
- Open Access
- 27 February 2026
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (2) , 1-10
Effect of Stenosis Severity on Outcomes After Rescue Stenting for Acute Middle Cerebral Artery Occlusions: a Real-world Multicenter Analysis
Purpose: Rescue stenting (RS) can achieve durable recanalization in cases of acute large vessel occlusion due to underlying intracranial artery stenosis (ICAS), but its clinical effects may be influenced by procedural factors. This study aimed to evaluate whether the severity of stenosis affects the outcomes after RS. Methods: In this multicenter retrospective study, patients with acute middle cerebral artery occlusion and underlying ICAS were divided into two groups based on the treatment they received: mechanical thrombectomy (MT) + RS ( n = 172) or MT-only ( n = 131). Inverse probability of treatment weighting was used to balance baseline characteristics. We systematically evaluated stenosis thresholds from 40% to 90% to identify the optimal cutoff that best differentiated treatment effects on the 90-day modified Rankin Scale (mRS) score and safety outcomes, including symptomatic intracranial hemorrhage (sICH). Results: A stenosis severity of 75% was identified as the optimal cutoff for effect modification. While RS improved recanalization rates overall, its effect on the 90-day mRS score was beneficial only in patients with > 75% stenosis compared to MT-only (Average Treatment Effect (ATE) −0.98, 95% CI −1.73 to −0.22; p = 0.01). In contrast, it showed a detrimental effect in those with < 75% stenosis (ATE 1.08, 95% CI 0.32 to 1.83; p = 0.005). Furthermore, RS increased the rate of sICH regardless of ICAS severity. Conclusions: The clinical benefit of RS is contingent on the underlying stenosis severity, providing favorable outcomes in patients with high-grade stenoses only. ICAS severity should also be considered for treatment decisions, though these findings require validation in prospective controlled studies.
- 27 February 2026
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (2) , 1-10
Open AccessEffect of Stenosis Severity on Outcomes After Rescue Stenting for Acute Middle Cerebral Artery Occlusions: a Real-world Multicenter Analysis
Purpose: Rescue stenting (RS) can achieve durable recanalization in cases of acute large vessel occlusion due to underlying intracranial artery stenosis (ICAS), but its clinical effects may be influenced by procedural factors. This study aimed to evaluate whether the severity of stenosis affects the outcomes after RS. Methods: In this multicenter retrospective study, patients with acute middle cerebral artery occlusion and underlying ICAS were divided into two groups based on the treatment they received: mechanical thrombectomy (MT) + RS ( n = 172) or MT-only ( n = 131). Inverse probability of treatment weighting was used to balance baseline characteristics. We systematically evaluated stenosis thresholds from 40% to 90% to identify the optimal cutoff that best differentiated treatment effects on the 90-day modified Rankin Scale (mRS) score and safety outcomes, including symptomatic intracranial hemorrhage (sICH). Results: A stenosis severity of 75% was identified as the optimal cutoff for effect modification. While RS improved recanalization rates overall, its effect on the 90-day mRS score was beneficial only in patients with > 75% stenosis compared to MT-only (Average Treatment Effect (ATE) −0.98, 95% CI −1.73 to −0.22; p = 0.01). In contrast, it showed a detrimental effect in those with < 75% stenosis (ATE 1.08, 95% CI 0.32 to 1.83; p = 0.005). Furthermore, RS increased the rate of sICH regardless of ICAS severity. Conclusions: The clinical benefit of RS is contingent on the underlying stenosis severity, providing favorable outcomes in patients with high-grade stenoses only. ICAS severity should also be considered for treatment decisions, though these findings require validation in prospective controlled studies.
- Open Access
- 13 October 2025
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (2) , 1-9
Impact of Stenting with Angioplasty and MTICI 2c-3 Recanalization On Outcome in Acute MCA Occlusion with Underlying Stenosis
Purpose: Mechanical thrombectomy (MT) is standard care for acute large vessel occlusion (LVO), but it fails in 10–20% of cases, often due to underlying intracranial artery stenosis (ICAS). In such cases, rescue stenting (RS), with or without angioplasty, may improve recanalization, but its clinical benefit remains debated. The purpose of this study was to define predictors of clinical outcome in this patient population. Methods: We conducted a retrospective multicenter study including 115 patients with ICAS-related occlusion of the middle cerebral artery (MCA) treated with MT and RS across 27 international stroke centers. Baseline, procedural, and post-procedural variables were analyzed. The outcome measure was the ordinal shift of the 90-day modified Rankin Scale (mRS) score. Stepwise multivariate regression and structural equation modeling (SEM) were used to identify outcome predictors and explore mediation pathways. Results: Successful recanalization (modified Treatment in Cerebral Infarction (mTICI) score ≥ 2b) was achieved in 94.8% of patients, with 73.0% reaching mTICI 2c‑3. SEM showed that baseline Alberta Stroke Program Early CT Score (ASPECTS), stenting with angioplasty and achieving mTICI 2c‑3 were associated with improved functional outcome, mediated by higher post-procedural ASPECTS. Post-procedural ASPECTS influenced functional outcome both directly (estimate = −0.45, p < 0.001) and indirectly by reducing the occurrence of symptomatic intracranial hemorrhage (sICH) (estimate = −0.09, p = 0.004). This model explained 36.5% of the variance in 90-day mRS scores. Conclusion: In patients with acute ICAS-related MCA occlusion, stenting with angioplasty and achieving mTICI 2c–3 recanalization are associated with improved clinical outcome. These benefits are mediated by better post-procedural ASPECTS and reduced sICH. Prospective studies are warranted to confirm these findings.
- 13 October 2025
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (2) , 1-9
Open AccessImpact of Stenting with Angioplasty and MTICI 2c-3 Recanalization On Outcome in Acute MCA Occlusion with Underlying Stenosis
Purpose: Mechanical thrombectomy (MT) is standard care for acute large vessel occlusion (LVO), but it fails in 10–20% of cases, often due to underlying intracranial artery stenosis (ICAS). In such cases, rescue stenting (RS), with or without angioplasty, may improve recanalization, but its clinical benefit remains debated. The purpose of this study was to define predictors of clinical outcome in this patient population. Methods: We conducted a retrospective multicenter study including 115 patients with ICAS-related occlusion of the middle cerebral artery (MCA) treated with MT and RS across 27 international stroke centers. Baseline, procedural, and post-procedural variables were analyzed. The outcome measure was the ordinal shift of the 90-day modified Rankin Scale (mRS) score. Stepwise multivariate regression and structural equation modeling (SEM) were used to identify outcome predictors and explore mediation pathways. Results: Successful recanalization (modified Treatment in Cerebral Infarction (mTICI) score ≥ 2b) was achieved in 94.8% of patients, with 73.0% reaching mTICI 2c‑3. SEM showed that baseline Alberta Stroke Program Early CT Score (ASPECTS), stenting with angioplasty and achieving mTICI 2c‑3 were associated with improved functional outcome, mediated by higher post-procedural ASPECTS. Post-procedural ASPECTS influenced functional outcome both directly (estimate = −0.45, p < 0.001) and indirectly by reducing the occurrence of symptomatic intracranial hemorrhage (sICH) (estimate = −0.09, p = 0.004). This model explained 36.5% of the variance in 90-day mRS scores. Conclusion: In patients with acute ICAS-related MCA occlusion, stenting with angioplasty and achieving mTICI 2c–3 recanalization are associated with improved clinical outcome. These benefits are mediated by better post-procedural ASPECTS and reduced sICH. Prospective studies are warranted to confirm these findings.
- Open Access
Elaboration and validation of R-LAST (Right Language Screening Test), a rapid and reliable screening tool to detect cognitive communication disorders in acute right hemisphere stroke
Background The role of the right hemisphere in language use and interpretive abilities has become clearer through studies describing sequelae in patients with right hemisphere stroke (RHS). Between 50% and 78% of stroke survivors with RHS experience communication disorders, a condition recently termed “apragmatism” by a group of experts. Apragmatism can negatively impact individuals’ personal lives and overall quality of life. Objective To develop and validate a bedside cognitive and communication screening tool for features of apragmatism in prospective patients with right stroke, called the Right Language Screening Test (R-LAST), which is simple, rapid, and suitable for emergency settings. Patients and methods R-LAST consists of seven subtests and twelve items. We report its internal and external validity and inter-rater reliability. We validated the scale by prospectively administering it to 300 patients admitted to two stroke units with confirmed right stroke, as well as to 94 stabilized patients with and without cognitive-communication disorders, using the MEC B as a reference. Results Internal validity demonstrated no redundancy with a Pearson coefficient less than 0.8. The internal consistency of the 12 items was questionable, indicated by a Cronbach’s alpha of 0.62. External validation against MEC B revealed a sensitivity of 0.84 and a specificity of 0.82. Inter-rater agreement was nearly perfect (ICC 0.993). The average time needed to complete R-LAST was 3 minutes and 52 seconds. Conclusion R-LAST could enable rapid and reliable detection of apragmatism in the acute phase of stroke, which could lead to timely referrals to speech-language therapists and ensure timely rehabilitation. This comprehensively validated cognitive-communication disorders rating scale is simple and rapid, making it a useful tool for bedside evaluation of acute stroke patients in routine clinical practice. Clinical Trial Registration Unique Identifier: NCT03622606 URL: https://clinicaltrials.gov/study/NCT03622606?term=R-LAST&rank=1
Open AccessElaboration and validation of R-LAST (Right Language Screening Test), a rapid and reliable screening tool to detect cognitive communication disorders in acute right hemisphere stroke
Background The role of the right hemisphere in language use and interpretive abilities has become clearer through studies describing sequelae in patients with right hemisphere stroke (RHS). Between 50% and 78% of stroke survivors with RHS experience communication disorders, a condition recently termed “apragmatism” by a group of experts. Apragmatism can negatively impact individuals’ personal lives and overall quality of life. Objective To develop and validate a bedside cognitive and communication screening tool for features of apragmatism in prospective patients with right stroke, called the Right Language Screening Test (R-LAST), which is simple, rapid, and suitable for emergency settings. Patients and methods R-LAST consists of seven subtests and twelve items. We report its internal and external validity and inter-rater reliability. We validated the scale by prospectively administering it to 300 patients admitted to two stroke units with confirmed right stroke, as well as to 94 stabilized patients with and without cognitive-communication disorders, using the MEC B as a reference. Results Internal validity demonstrated no redundancy with a Pearson coefficient less than 0.8. The internal consistency of the 12 items was questionable, indicated by a Cronbach’s alpha of 0.62. External validation against MEC B revealed a sensitivity of 0.84 and a specificity of 0.82. Inter-rater agreement was nearly perfect (ICC 0.993). The average time needed to complete R-LAST was 3 minutes and 52 seconds. Conclusion R-LAST could enable rapid and reliable detection of apragmatism in the acute phase of stroke, which could lead to timely referrals to speech-language therapists and ensure timely rehabilitation. This comprehensively validated cognitive-communication disorders rating scale is simple and rapid, making it a useful tool for bedside evaluation of acute stroke patients in routine clinical practice. Clinical Trial Registration Unique Identifier: NCT03622606 URL: https://clinicaltrials.gov/study/NCT03622606?term=R-LAST&rank=1
- Open Access
Efficacy of Simultaneous Infusion of Tirofiban with Intravenous Thrombolysis in Patients with Acute Anterior Choroidal or Paramedian Pontine Infarction: TITACIPPI Study
Background and Purpose: Intravenous thrombolysis combined with tirofiban (IVT plus tirofiban) has been reported to be more effective than IVT alone in preventing early neurological deterioration (END) and improving 3-month functional outcomes in patients with ischemic stroke. This study aimed to assess the radiological efficacy and safety of simultaneous (or within 60 minutes) IVT plus tirofiban versus IVT alone specifically in patients with anterior choroidal infarction (ACI) or paramedian pontine infarction (PPI), two subtypes with a high risk of END. Methods: We conducted a single-center, retrospective study including consecutive patients aged ≥18 years treated during two distinct periods: one with standard IVT alone and one with IVT plus tirofiban. The primary endpoint was ≥20% reduction in lesion volume on 24-hour diffusion-weighted imaging (DWI). Secondary endpoints included early clinical improvement at 24 hours and 7 days (or discharge), functional independence (modified Rankin Scale (mRS) scores ≤2 and ≤1) at 3 months, and END. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and major systemic bleeding (MSB). A subgroup analysis compared clinical outcomes in patients with « lesion reversal » versus patients with no « lesion reversal ». Results: A total of 58 patients were analyzed (30 IVT plus tirofiban; 28 IVT alone). Lesion reversal ≥20% was more frequently observed in the IVT plus tirofiban group (adjusted odds ratio, 8.58; 95% CI, 2.09–35.28; p=0.001). No significant differences were found between groups for END or 3-month functional outcomes (mRS ≤2 or ≤1). One non-fatal MSB occurred in the IVT alone group. No cases of sICH were observed in either group. Overall lesion reversal was significantly associated with better early and late outcomes, and with IVT plus tirofiban treatment. Discussion and Conclusions: This study suggests that IVT plus tirofiban improves radiological outcomes and may be a promising therapeutic option in patients with ACI/PPI, without increasing the risk of bleeding compared to IVT alone. KEY MESSAGE: What is already known on this topic: Branch atheromatous disease related ischemic strokes (BADRIS) carry a substantial risk of long-term disability because early neurological deterioration (END) is frequent even after intravenous thrombolysis (IVT). However, the role of IVT in preventing END in patients with BADRIS is not well established. What this study adds: This single-center retrospective study provides real-world evidence that IVT plus tirofiban is associated with a lesion reversal ≥20% on 24-hour diffusion-weighted imaging (DWI) compared to IVT alone. The study also provides evidence that lesion reversal is associated with better early and late outcomes, and with IVT plus tirofiban treatment. How this study might affect research, practice or policy: These findings support the use of IVT plus tirofiban in patients with BADRIS. This combination promotes lesion reversal, thereby improving functional outcomes and reducing the risk of END. Larger prospective multicenter randomized trials are needed to confirm these findings and to determine whether this strategy provides a functional benefit at 3 months.
Open AccessEfficacy of Simultaneous Infusion of Tirofiban with Intravenous Thrombolysis in Patients with Acute Anterior Choroidal or Paramedian Pontine Infarction: TITACIPPI Study
Background and Purpose: Intravenous thrombolysis combined with tirofiban (IVT plus tirofiban) has been reported to be more effective than IVT alone in preventing early neurological deterioration (END) and improving 3-month functional outcomes in patients with ischemic stroke. This study aimed to assess the radiological efficacy and safety of simultaneous (or within 60 minutes) IVT plus tirofiban versus IVT alone specifically in patients with anterior choroidal infarction (ACI) or paramedian pontine infarction (PPI), two subtypes with a high risk of END. Methods: We conducted a single-center, retrospective study including consecutive patients aged ≥18 years treated during two distinct periods: one with standard IVT alone and one with IVT plus tirofiban. The primary endpoint was ≥20% reduction in lesion volume on 24-hour diffusion-weighted imaging (DWI). Secondary endpoints included early clinical improvement at 24 hours and 7 days (or discharge), functional independence (modified Rankin Scale (mRS) scores ≤2 and ≤1) at 3 months, and END. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and major systemic bleeding (MSB). A subgroup analysis compared clinical outcomes in patients with « lesion reversal » versus patients with no « lesion reversal ». Results: A total of 58 patients were analyzed (30 IVT plus tirofiban; 28 IVT alone). Lesion reversal ≥20% was more frequently observed in the IVT plus tirofiban group (adjusted odds ratio, 8.58; 95% CI, 2.09–35.28; p=0.001). No significant differences were found between groups for END or 3-month functional outcomes (mRS ≤2 or ≤1). One non-fatal MSB occurred in the IVT alone group. No cases of sICH were observed in either group. Overall lesion reversal was significantly associated with better early and late outcomes, and with IVT plus tirofiban treatment. Discussion and Conclusions: This study suggests that IVT plus tirofiban improves radiological outcomes and may be a promising therapeutic option in patients with ACI/PPI, without increasing the risk of bleeding compared to IVT alone. KEY MESSAGE: What is already known on this topic: Branch atheromatous disease related ischemic strokes (BADRIS) carry a substantial risk of long-term disability because early neurological deterioration (END) is frequent even after intravenous thrombolysis (IVT). However, the role of IVT in preventing END in patients with BADRIS is not well established. What this study adds: This single-center retrospective study provides real-world evidence that IVT plus tirofiban is associated with a lesion reversal ≥20% on 24-hour diffusion-weighted imaging (DWI) compared to IVT alone. The study also provides evidence that lesion reversal is associated with better early and late outcomes, and with IVT plus tirofiban treatment. How this study might affect research, practice or policy: These findings support the use of IVT plus tirofiban in patients with BADRIS. This combination promotes lesion reversal, thereby improving functional outcomes and reducing the risk of END. Larger prospective multicenter randomized trials are needed to confirm these findings and to determine whether this strategy provides a functional benefit at 3 months.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2091-2100
Delay in Carotid Web Diagnosis Remains Common and Associated With an Increased Risk of Stroke Recurrence
BACKGROUND: Carotid web is a rare and likely underrecognized cause of ischemic stroke, particularly in young patients. Given the high risk of recurrence, diagnostic delays may have serious consequences. This study aimed to assess the incidence and impact of delayed carotid web diagnosis after a first ischemic event. METHODS: We conducted a retrospective analysis using data from the French ongoing multicenter prospective CAROWEB (Carotid Web registry). We included patients with a first-ever ischemic stroke or transient ischemic attack in the anterior circulation, attributed to an ipsilateral carotid web with no other identifiable cause, between September 2013 and April 2023. Patients with missing data on the date of the first ischemic event or carotid web diagnosis, or with prior stroke history, were excluded. Participants were categorized into early diagnosis (≤30 days) and delayed diagnosis (>30 days) groups. Factors associated with diagnostic delay were investigated through univariable and multivariable analyses. Stroke recurrence was evaluated using Kaplan-Meier survival analysis. RESULTS: Of 280 patients in the registry, 225 met the inclusion criteria. A delayed diagnosis occurred in 57 patients (25.3%). Independent predictors of diagnostic delay included lower initial National Institutes of Health Stroke Scale score (odds ratio, 0.92; P =0.002), stroke occurring before 2019 (odds ratio, 0.19; P P P =0.014). CONCLUSIONS: Delayed carotid web diagnosis remains common, especially in minor strokes, in the absence of early computed tomography angiography, and in events before 2019. Such delays are associated with a significantly increased risk of stroke recurrence, highlighting the need for early vascular imaging in ischemic stroke evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04431609.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2091-2100
Delay in Carotid Web Diagnosis Remains Common and Associated With an Increased Risk of Stroke Recurrence
BACKGROUND: Carotid web is a rare and likely underrecognized cause of ischemic stroke, particularly in young patients. Given the high risk of recurrence, diagnostic delays may have serious consequences. This study aimed to assess the incidence and impact of delayed carotid web diagnosis after a first ischemic event. METHODS: We conducted a retrospective analysis using data from the French ongoing multicenter prospective CAROWEB (Carotid Web registry). We included patients with a first-ever ischemic stroke or transient ischemic attack in the anterior circulation, attributed to an ipsilateral carotid web with no other identifiable cause, between September 2013 and April 2023. Patients with missing data on the date of the first ischemic event or carotid web diagnosis, or with prior stroke history, were excluded. Participants were categorized into early diagnosis (≤30 days) and delayed diagnosis (>30 days) groups. Factors associated with diagnostic delay were investigated through univariable and multivariable analyses. Stroke recurrence was evaluated using Kaplan-Meier survival analysis. RESULTS: Of 280 patients in the registry, 225 met the inclusion criteria. A delayed diagnosis occurred in 57 patients (25.3%). Independent predictors of diagnostic delay included lower initial National Institutes of Health Stroke Scale score (odds ratio, 0.92; P =0.002), stroke occurring before 2019 (odds ratio, 0.19; P P P =0.014). CONCLUSIONS: Delayed carotid web diagnosis remains common, especially in minor strokes, in the absence of early computed tomography angiography, and in events before 2019. Such delays are associated with a significantly increased risk of stroke recurrence, highlighting the need for early vascular imaging in ischemic stroke evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04431609.
- 1 October 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (10) , 2491-2499
Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase
BACKGROUND: Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke. There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before mechanical thrombectomy, and little data on their potential differences stratified by ER predictors such as IVT to ER evaluation (IVT-to-ER eval ) time, occlusion site and thrombus length. METHODS: We retrospectively compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation large-vessel occlusion acute ischemic stroke patients from the PREDICT-RECANAL (alteplase) and Tenecteplase Treatment in Ischemic Stroke (tenecteplase) French multicenter registries. ER was defined as a modified Thrombolysis in Cerebral Infarction score 2b-3 on the first angiographic run, or noninvasive vascular imaging in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (leading to exact balance in patient history, stroke characteristics, and initial management between groups) and confirmed with adjusted logistic regression (sensitivity analysis). A stratified analysis based on pre-established ER predictors (IVT-to-ER eval time, occlusion site, and thrombus length) was conducted. RESULTS: Overall, 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95% CI, 0.83–1.44]; P =0.52). A differential effect of tenecteplase versus alteplase on the probability of ER according to thrombus length was observed ( P interaction =0.003), with tenecteplase being associated with higher odds of ER in thrombi >10 mm (odds ratio, 2.43 [95% CI, 1.02–5.81]; P =0.04). There was no differential effect of tenecteplase versus alteplase on the likelihood of ER according to the IVT-to-ER eval time ( P interaction =0.40) or occlusion site ( P interaction =0.80). CONCLUSIONS: Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-ER eval time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.
- 1 October 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (10) , 2491-2499
Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase
BACKGROUND: Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke. There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before mechanical thrombectomy, and little data on their potential differences stratified by ER predictors such as IVT to ER evaluation (IVT-to-ER eval ) time, occlusion site and thrombus length. METHODS: We retrospectively compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation large-vessel occlusion acute ischemic stroke patients from the PREDICT-RECANAL (alteplase) and Tenecteplase Treatment in Ischemic Stroke (tenecteplase) French multicenter registries. ER was defined as a modified Thrombolysis in Cerebral Infarction score 2b-3 on the first angiographic run, or noninvasive vascular imaging in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (leading to exact balance in patient history, stroke characteristics, and initial management between groups) and confirmed with adjusted logistic regression (sensitivity analysis). A stratified analysis based on pre-established ER predictors (IVT-to-ER eval time, occlusion site, and thrombus length) was conducted. RESULTS: Overall, 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95% CI, 0.83–1.44]; P =0.52). A differential effect of tenecteplase versus alteplase on the probability of ER according to thrombus length was observed ( P interaction =0.003), with tenecteplase being associated with higher odds of ER in thrombi >10 mm (odds ratio, 2.43 [95% CI, 1.02–5.81]; P =0.04). There was no differential effect of tenecteplase versus alteplase on the likelihood of ER according to the IVT-to-ER eval time ( P interaction =0.40) or occlusion site ( P interaction =0.80). CONCLUSIONS: Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-ER eval time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.